{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":16,"n_cols":16,"rows_kept":16,"flags":["formulas_cached_only"]}
[{"$nulls":11},"Supplementary Data 1: Clinical and pathological information of 191 cases HCC patients (cohort 1)"]
[{"$nulls":12},"YAP R124me2a High Level with sorafenib teatment （n=49)","YAP R124me2a High Level without sorafenib teatment (n=44)","YAP R124me2a Low Level with sorafenib teatment (n=49)","YAP R124me2a Low Level without sorafenib teatment (n=50)"]
[{"$nulls":11},"Age","46.75±10.51","53.06±11.41","47.22±10.43","51.02±10.75"]
[{"$nulls":11},"Sex"]
[{"$nulls":11},"Male","45（93.75%）","39（88.64%）","44（89.80%）","47(94%)"]
[{"$nulls":11},"Female","3（6.25%）","5（11.36%）","5（10.20%)","3(6%)"]
[{"$nulls":11},"Grade"]
[{"$nulls":11},"Ⅰ","0(0%)","0(0%)","0(0%)","1（2%）"]
[{"$nulls":11},"Ⅱ","5(10.42%)","19（43.18%）","7（14.29%）","21(42%）"]
[{"$nulls":11},"Ⅲ","41(85.42%)","25（56.82%）","42（85.71%）","28（56%）"]
[{"$nulls":11},"Ⅳ","2(4.17%）","0(0%)","0(0%)","0(0%)"]
[{"$nulls":11},"AJCC"]
[{"$nulls":11},1,"22（45.83%）","16(30.19%)","33(67.35%)","10（21.74%）"]
[{"$nulls":11},2,"26（54.17）","24(45.28%)","16(32.65%)","15（32.61%）"]
[{"$nulls":11},3,"0(0%)","13(24.53%)",0,"19（41.30）"]
[{"$nulls":11},4,"0(0%)","0(0%)","0(0%)","2（4.35%）"]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}